Pyridazine-Based mGlu Modulators
Novel class of reversible allosteric modulators targeting mGlu1 and mGlu5 with structure-driven selectivity in cortical neuron assays.
bioRxiv
Research Assistant II
Mallory A. Maurer
Research Assistant II at the Cha Lab, exploring chemical biology strategies to study neural GPCRs and neuromodulatory systems. Formerly at Vanderbilt's Warren Center for Neuroscience Drug Discovery. Applying to biomedical engineering PhD programs in Fall 2025.
Research Highlights
Serotonin 5-HT2 Agonists
Structure–activity study of indazole tryptamine analogs probing 5-HT2 receptor subtype selectivity.
PubMedmGlu5 NAM Series
Discovery of potent, brain-penetrant NAMs targeting mGlu5 receptors through scaffold-hopping optimization.
PubMed
Selected Publications
Selective, Reversible Chemical Modulation of mGlu1 and mGlu5 by Novel Pyridazine Derivatives
bioRxiv, 2025
Introduces a new class of pyridazine-based allosteric modulators targeting mGlu1 and mGlu5, revealing structure-driven selectivity profiles in cortical neuron assays.
Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists
ACS Med Chem Lett, 2024
Synthesizes and profiles indazole analogs of 5-MeO-DMT to map SAR at 5-HT2 receptors, identifying subtype-selective agonists.
Discovery of Thieno[3,2-b]pyridine-5-carboxamide and 2,3-Difluorobenzamide NAMs of mGlu5
ACS Med Chem Lett, 2025
Expands mGlu5 NAM series with new chemotypes and improved selectivity.
Development of VU6036864: A Triazolopyridine-Based High-Quality Antagonist Tool Compound of the M5 Muscarinic Receptor
J. Med. Chem., 2024
Reports discovery of a potent and selective M5 antagonist suitable as a neuroscience tool compound.
Discovery of 4-(5-Membered)Heteroarylether-6-methylpicolinamide Negative Allosteric Modulators of mGlu5
ACS Med Chem Lett, 2024
Describes novel mGlu5 NAMs with optimized brain penetration and pharmacology.
Contact
LinkedIn: linkedin.com/in/mallory-maurer-25b1a3229
Current Role: Research Assistant II at the Cha Lab, Chemical Biology & GPCR Research
Previous: Warren Center for Neuroscience Drug Discovery, Vanderbilt University
Status: Applying to PhD programs in Fall 2025